Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? Journal Article

Local Library Link: Find It @ Loyola

Authors: Burstein, H. J.; Piccart-Gebhart, M. J.; Perez, E. A.; Hortobagyi, G. N.; Wolmark, N.; Albain, K. S.; Norton, L; Winer, E. P.; Hudis, C. A.
Article Title: Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Journal Title: Journal of Clinical Oncology
Volume: 30
Issue: 18
ISSN: 0732-183X
Publisher: Unknown  
Journal Place: United States
Date Published: 2012
Start Page: 2179
End Page: 2182
Language: eng
DOI/URL:

10.1200/JCO.2012.42.0695

10.1200/JCO.2012.42.0695
Notes: LR: 20130508; JID: 8309333; 0 (Anthracyclines); 0 (Antibodies, Monoclonal, Humanized); EC 2.7.10.1 (Receptor, erbB-2); P188ANX8CK (trastuzumab); CIN: J Clin Oncol. 2012 Dec 10;30(35):4445-6; author reply 4446. PMID: 23071231; 2012/05/21 [aheadofprint]; ppublish
LUC Authors
  1. Kathy S. Albain
    34 Albain